Research Paper Volume 16, Issue 6 pp 5050—5064

Figure 3. Omilancor reduced cellular senescence by regulating MAP2K6. (A) The top 5 drugs and their corresponding binding energies (kcal/mol) predicted as potential inhibitors for MAP2K6. (B) RT-qPCR results revealing that Omilancor exhibited the most significant inhibitory effect on MAP2K6 expression (5ug/ml, 12h, n=3 each group). (C, D) Ligand interaction diagrams depicting the top-scoring molecular docking complexes between OMLC and MAP2K6 proteins (RMSD = 2.206; estimated free energy of binding = -12.1 kcal/mol). (E) Western blot analysis illustrating the expression levels of MAP2K6 and P21 following treatments with DDP and OMLC. (F) Immunocytochemistry (ICC) staining demonstrating the expression of MAP2K6 in rat NP cells subjected to various treatments. (Original magnification 400×, scale bar = 100 μm). (G, H) SA-β-gal staining and the corresponding quantitative analysis of rat NP cells under different treatment conditions. (Original magnification 100×, scale bar = 400 μm). Red arrow: positive cells). CTR, control group; DDP, cisplatin treatment; OMLC, Omilancor treatment. n = 3 each group. Data are represented as mean ± standard deviation. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001, as determined by one-way ANOVA with post-hoc Bonferroni correction or Kruskal-Wallis H test with a Dunn’s correction.